Document:

Exhibit 10.1

 

 

 

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES
PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 21, 2021 (the “Effective
Date”) by and among Milestone Pharmaceuticals Inc., a corporation continuing under the Business Corporations Act
(Québec) (the “Company”) and each of those persons listed as a Purchaser on the Schedule of Purchasers
attached as Schedule I hereto (each, a “Purchaser” and together, the “Purchasers”).
Certain terms used and not otherwise defined in the text of this Agreement are defined in Section 11 hereof.

 

RECITALS

 

WHEREAS, the
Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and/or Rule 506 of Regulation
D as promulgated by the United States Securities and Exchange Commission (the “Commission”) under the Securities
Act; and

 

WHEREAS,
the Company desires to sell to the Purchasers, and the Purchasers desire to purchase from the Company, one or more pre-funded warrants
issued by the Company to purchase up to 910,746 Company common shares, no par value per share (the “Common Shares”)
at an exercise price of $0.01 per share (the “Warrant Shares”) in substantially the form attached hereto as
Exhibit A (the “Pre-Funded Warrants”);

 

NOW, THEREFORE,
in consideration of the foregoing and the mutual representations, warranties and covenants herein contained, the parties hereto hereby
agree as follows:

 

Section
1.   Authorization of Warrants. The Company has authorized the sale and issuance of the Pre-Funded Warrants on the terms
and subject to the conditions set forth in this Agreement.

 

Section 2.  Sale
and Purchase of the Pre-Funded Warrants.

 

2.1             
Upon the terms and subject to the conditions herein contained, the Company agrees to sell to the Purchasers, and the Purchasers
agree to purchase from the Company, at the Closing (as defined in Section 3), that number of Pre-Funded Warrants set forth on Schedule
I hereto (the “Schedule of Purchasers”) for the purchase price set forth opposite such Purchaser’s name,
which amount represents the number of Pre-Funded Warrants purchased by such Purchaser multiplied by the price per Pre-Funded Warrants
of $5.48. The purchase price to be paid by each Purchaser, as set forth on Schedule I, shall be referred to as the “Aggregate
Purchase Price.”

 

2.2             
At or prior to the Closing, each Purchaser will pay the purchase price set forth opposite such Purchaser’s name on
Schedule I by wire transfer of immediately available funds in accordance with wire instructions provided by the Company to the Purchasers
prior to the Closing. On or before the Closing, the Company will deliver duly executed Pre-Funded Warrants to the Purchasers, in each
case against delivery of the Aggregate Purchase Price.

 

     

     

    

 

Section
3   Closing. Subject to the satisfaction of the closing conditions set forth in Section 7, the closing with
respect to the transactions contemplated in Section 2 hereof (the “Closing”), shall take place at the offices
of Cooley LLP, 500 Boylston Street, 14th Floor, Boston, MA 02116 on the second Business Day after the Effective Date (the
“Closing Date”) or at such other time and place as the Company and Purchasers may agree, including remotely
via the exchange of documents and signatures.

 

Section
4.   Representations and Warranties of the Purchaser. Each Purchaser represents and warrants to the Company that the statements
contained in this Section 4 are true and correct as of the Effective Date, and will be true and correct as of the date of the Closing
Date:

 

4.1            
Validity. The execution, delivery and performance of this Agreement, including the purchase of the Pre-Funded Warrants
and the other instruments referred to herein, in each case to which such Purchaser is a party, and the consummation by such Purchaser
of the transactions contemplated hereby have been duly authorized by all necessary corporate, partnership, limited liability or similar
actions, as applicable, on the part of such Purchaser. This Agreement has been duly executed and delivered by such Purchaser, and the
other instruments referred to herein to which it is a party will be duly executed and delivered by such Purchaser, and each such agreement
and other instruments constitutes or will constitute a valid and binding obligation of such Purchaser, enforceable against it in accordance
with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other
laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the availability
of specific performance, injunctive relief, or other equitable remedies.

 

4.2             
Brokers. There is no broker, investment banker, financial advisor, finder or other Person that has been retained
by or is authorized to act on behalf of such Purchaser who might be entitled to any fee or commission for which the Company will be liable
in connection with the execution of this Agreement and the consummation of the transactions contemplated hereby.

 

4.3             
Investment Representations and Warranties. Such Purchaser understands and agrees that the offering and sale of the
Pre-Funded Warrants and the Warrant Shares has not been registered under the Securities Act or any applicable state securities laws and
are being made in reliance upon federal and state exemptions for transactions not involving a public offering that depend upon, among
other things, the bona fide nature of the investment intent and the accuracy of such Purchaser’s representations as expressed herein.

 

4.4            
Acquisition for Own Account; No Control Intent. Such Purchaser is acquiring the Pre-Funded Warrant and the Warrant
Shares for its own account for investment and not with a view toward distribution in a manner that would violate the Securities Act or
any applicable state securities laws. Such Purchaser is not a broker or dealer registered pursuant to Section 15 of the Exchange Act (a
“registered broker-dealer”) and is not affiliated with a registered broker dealer. Such Purchaser is not party to any agreement
providing for or contemplating the distribution of any of the Pre-Funded Warrants or the Warrant Shares. Such Purchaser has no present
intent to effect a “change of control” of the Company as such term is understood under the rules promulgated pursuant to Section
13(d) of the Exchange Act.

 

    2 

     

    

 

4.5            
 Ability to Protect Its Own Interests and Bear Economic Risks. Such Purchaser, by reason of the business and financial
experience of its management, has the capacity to protect its own interests in connection with the transactions contemplated by this Agreement
and is capable of evaluating the merits and risks of the investment in the Pre-Funded Warrants and the Warrant Shares. Such Purchaser
is able to bear the economic risk of an investment in the Pre- Funded Warrants and the Warrant Shares and is able to sustain a loss of
all of its investment in the Pre-Funded Warrants without economic hardship, if such a loss should occur.

 

4.6             
Accredited Investor; No Bad Actor. Such Purchaser is an “accredited investor” as that term is defined
in Rule 501(a) under the Securities Act, a “Qualified Institutional Buyer” as defined in Rule 144A under the Securities Act,
and a “qualified purchaser” as defined in Section 2(a)(51) of the Investment Company Act of 1940, as amended. Such Purchaser
has not taken any of the actions set forth in, and is not subject to, the disqualification provisions of Rule 506(d)(1) of the Securities
Act. Such Purchaser is also an “accredited investor” within the meaning of Regulation 45-106 respecting Prospectus Exemptions
on the basis that such Purchaser fits within one of the categories of an “accredited investor” which such Purchaser has
indicated it so belongs and has provided confirmation of same to the Company. Such Purchaser is also acquiring the Pre-Funded Warrants
and the Warrant Shares as principal and has not been created, or is being used, solely to purchase or hold the Pre-Funded Warrants and
the Warrant Shares.

 

4.7            
Access to Information. Such Purchaser has been given access to Company documents, records, and other information,
and has had adequate opportunity to ask questions of, and receive answers from, the Company’s officers, employees, agents, accountants,
and representatives concerning the Company’s business, operations, financial condition, assets, liabilities, and all other matters
relevant to its investment in the Pre-Funded Warrants and the Warrant Shares. Such Purchaser understands that an investment in the Pre-Funded
Warrants and the Warrant Shares bears significant risk and represents that it has reviewed the SEC Reports (defined below), which serve
to qualify certain of the Company representations set forth below.

 

		4.8	Restricted Securities.

 

(a)              
Such Purchaser understands that the Pre-Funded Warrants and the Warrant Shares will be characterized as “restricted
securities” under the federal securities laws inasmuch as they are being acquired from the Company in a private placement under
Section 4(a)(2) of the Securities Act and/or the applicable provisions of Regulation D promulgated thereunder, and that under such laws
and applicable regulations such Pre- Funded Warrants and Warrant Shares may be resold without registration under the Securities Act only
in certain limited circumstances.

 

(b)             
Such Purchaser acknowledges that the Pre-Funded Warrants and the Warrant Shares must be held indefinitely unless subsequently
registered under the Securities Act and under applicable state securities laws or an exemption from such registration is available. Such
Purchaser understands that the Company is under no obligation to register the Pre-Funded Warrants or the Warrant Shares, except as provided
in this Agreement.

 

(c)             
 Such Purchaser is aware of the provisions of Rule 144 under the Securities Act, which permit limited resale of securities
purchased in a private placement.

 

    3 

     

    

 

4.9             
Such Purchaser has a substantive, pre-existing relationship with the Company and the management of the Company.

 

4.10         
Such Purchaser became aware of the Pre-Funded Warrants and the Warrant Shares, and the Pre-Funded Warrants and the Warrant
Shares were offered to such Purchaser, solely by direct contact between such Purchaser and the Company, and not by any other means, and
such Purchaser is unaware of, and is in no way relying on, any form of general solicitation or general advertising, including, without
limitation, any article, notice, advertisement or other communication published in any newspaper, magazine or similar media or broadcast
over television or radio, or electronic mail over the Internet, in connection with the offer and sale of the Pre-Funded Warrants and the
Warrant Shares, and is not subscribing for the Pre-Funded Warrants and the Warrant Shares and did not become aware of the Pre-Funded Warrants
or the Warrant Shares through or as a result of any seminar or meeting to which such Purchaser was invited by, or any solicitation of
a subscription by, a person not previously known to such Purchaser in connection with investments in securities generally.

 

Section
5   Representations and Warranties by the Company. Assuming the accuracy of the representations and warranties of the
Purchasers set forth in Article 4 and except as set forth in the SEC Reports, which disclosures serve to qualify these representations
and warranties in their entirety, the Company represents and warrants to the Purchasers that the statements contained in this Section
5 are true and correct in all material respects as of the Effective Date, and will be true and correct in all material respects as of
the date of the Closing Date:

 

5.1             
Organization and Good Standing. The Company and each Subsidiary: (a) is duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its formation, (b) is duly qualified to do business as a foreign
entity and is in good standing in each jurisdiction where the nature of the property owned or leased by it or the nature of the business
conducted by it makes such qualification necessary, except where the failure to be so qualified would not have a Material Adverse Effect,
and (c) has all requisite corporate power and authority to own or lease and operate its assets and carry on its business as presently
being conducted as disclosed in the SEC Reports.

 

		5.2	Corporate Power and Authority; Valid Issuance of Warrants.

 

(a)               The
Company has all requisite corporate power and has taken all necessary corporate action required for the due authorization,
execution, delivery and performance by the Company of this Agreement and the other Transaction Documents and the consummation of the
transactions contemplated hereby and thereby. The execution, delivery and performance by the Company of this Agreement, and the
consummation by the Company of the transactions contemplated hereby, have been duly authorized by the Company’s board of
directors or a duly authorized committee thereof and no further consent or authorization of the Company, its board of directors or
its shareholders is required. This Agreement has been duly executed and delivered by the Company, and the other instruments referred
to herein to which it is a party will be duly executed and delivered by the Company, and each such agreement constitutes or will
constitute a legal, valid and binding obligation of the Company enforceable against it in accordance with its terms, except to the
extent that enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any
other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the
availability of specific performance, injunctive relief, or other equitable remedies.

 

    4 

     

    

 

(b)              
Each Pre-Funded Warrant, upon delivery, will have been duly executed by the Company and, when delivered in accordance with
the terms hereof, will constitute a valid and binding obligation of the Company enforceable against the Company in accordance with its
terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other
laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law. The Warrant Shares, when issued and delivered upon exercise of each Pre-Funded Warrant in accordance
with its terms, will be validly issued, fully paid and non-assessable and free of any preemptive or similar rights.

 

5.3           
Consents. Neither the execution, delivery or performance of this Agreement by the Company, nor the consummation by
it of the obligations and transactions contemplated hereby (including, without limitation, the issuance, the delivery of the Pre-Funded
Warrants and the provision to the Purchasers of the rights contemplated by the Transaction Documents) requires any consent of, authorization
by, exemption from, filing with or notice to any Governmental Entity or any other Person, other than filings required under applicable
U.S. or Canadian federal and state securities laws.

 

		5.4	No Conflicts.

 

(a)               The
execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby (including,
without limitation, the execution and delivery of the Pre-Funded Warrants, and, upon the valid exercise of the Pre-Funded Warrants,
the delivery of the Warrant Shares and the provision to the Purchasers of the rights contemplated by the Transaction Documents) will
not (a) result in a violation of articles or by- laws, as amended, or any equivalent organizational document of the Company or any
Subsidiary (the “Charter Documents”) or require the approval of the Company’s shareholders, (b)
violate, conflict with or result in the breach of the terms, conditions or provisions of or constitute a default (or an event which
with notice or lapse of time or both would become a default) under, or give rise to any right of termination, acceleration or
cancellation under, any material agreement, lease, mortgage, license, indenture, instrument or other contract to which the Company
or any Subsidiary is a party, (c) result in a violation of any law, rule, regulation, order, judgment or decree (including, without
limitation, U.S. or Canadian federal and state securities laws and regulations and regulations of any self-regulatory organizations
to which the Company or its securities are subject) applicable to the Company or any Subsidiary or by which any property or asset of
the Company or any Subsidiary is bound or affected, (d) result in a violation of or require shareholder approval under any rule or
regulation of The Nasdaq Stock Market, or (e) result in the creation of any encumbrance upon any of the Company’s or any of
its Subsidiary’s assets.

 

    5 

     

    

 

(b)              
Neither the Company nor any Subsidiary is (i) in violation of its Charter Documents, (ii) in default (and no event has occurred
that, with notice or lapse of time or both, would cause the Company or any Subsidiary to be in default) under, nor has there occurred
any event giving others (with notice or lapse of time or both) any rights of termination, amendment, acceleration or cancellation of,
any material agreement, indenture or instrument to which the Company or any Subsidiary is a party, nor has the Company or any Subsidiary
received written notice of a claim that it is in default under, or that it is in violation of, any material contract (whether or not such
default or violation has been waived), (iii) in violation of, or in receipt of written notice that it is in violation of, any law, ordinance
or regulation of any Governmental Entity, except where the violation would not result in a Material Adverse Effect, and (iv) in violation
of any order of any Governmental Entity having jurisdictional over the Company or any Subsidiary or any of the Company’s or any
Subsidiary’s properties or assets.

 

5.5           
Québec Securities Laws. The Company has complied with the securities laws of the Province of Québec,
including the rules and regulations made thereunder together with applicable published national and local instruments, policy statements,
notices, blanket rulings and orders of the Autorité des marchés financiers (Québec), and all discretionary
rulings and orders applicable to the Company, if any, of the Canadian securities commissions required to be complied with by the Company
in order to sell the Pre-Funded Warrants and the Warrant Shares outside Canada as contemplated by this Agreement. To the Company’s
knowledge, no order, ruling or decision of any court or any securities regulatory authority in Canada is in effect that restricts or ceases
trades in securities of the Company.

 

5.6             
The Nasdaq Stock Market. The Common Shares are listed on The Nasdaq Global Select Market. To the Company’s
knowledge, there are no proceedings to revoke or suspend such listing or the listing of the Common Shares. The Company is in compliance
with the requirements of Nasdaq for continued listing of the Common Shares thereon and any other Nasdaq listing and maintenance requirements,
and the execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated
hereby (including the issuance of the Pre-Funded Warrants) will not result in any noncompliance by the Company with any such requirements.

 

5.7              No
Integrated Offering. Neither the Company, any Subsidiary, nor any of the Company’s or any Subsidiary’s Affiliates or
any other Person acting on the Company’s or any Subsidiary’s behalf, has directly or indirectly engaged in any form of
general solicitation or general advertising with respect to the Pre-Funded Warrants, nor have any of such Persons made any offers or
sales of any security of the Company, any Subsidiary or any of the Company’s or any Subsidiary’s Affiliates or solicited
any offers to buy any security of the Company, any Subsidiary or any of the Company’s or any Subsidiary’s Affiliates
under circumstances that would require registration of the Pre-Funded Warrants under the Securities Act or any other securities laws
or cause this offering of Pre-Funded Warrants to be integrated with any prior offering of securities of the Company or any
Subsidiary for purposes of the Securities Act in any manner that would affect the validity of the private placement exemption under
the Securities Act for the offer and sale of the Pre-Funded Warrants hereunder.

 

    6 

     

    

 

		5.8	SEC Reports; Financial Statements; Shell Company Status.

 

(a)              
The Company’s Common Shares are registered under Section 12 of the Exchange Act. The Company has filed all reports,
schedules, forms, statements and other documents required to be filed by the Company under the Exchange Act, including pursuant to Section
13(a) or 15(d) thereof, since May 8, 2019 (the foregoing materials, including the exhibits thereto and documents incorporated by reference
therein, being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid
extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective
dates, the SEC Reports complied in all material respects with the requirements of the Exchange Act and, in each case, to the rules promulgated
thereunder, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading.

 

(b)              
The financial statements and the related notes of the Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time
of filing. Such financial statements have been prepared in accordance with GAAP, except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly
present the consolidated financial position of the Company as of and for the dates thereof and the consolidated results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
There is no transaction, arrangement, or other relationship between the Company or any Subsidiary and an unconsolidated or other off balance
sheet entity that is required to be disclosed by the Company in SEC Reports and is not so disclosed and would have or reasonably be expected
to result in a Material Adverse Effect.

 

(c)              
The Company is not, and has never been, an issuer identified in Rule 144(i)(1) under the Securities Act.

 

		5.9	Disclosure Controls and Procedures; Internal Controls Over Financial Reporting.

 

(a)              The
Company has established and maintains disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
that are effective in all material respects to ensure that material information relating to the Company, including any consolidated
Subsidiaries, is made known to its principal executive officer and principal financial officer by others within those entities. The
Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of
the end of the period covered by the most recently filed quarterly or annual periodic report under the Exchange Act (such date, the
“Evaluation Date”). The Company presented in its most recently filed quarterly or annual periodic report
under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the Evaluation Date.

 

    7 

     

    

 

(b)              
The Company maintains internal control over financial reporting (as such term is defined in Exchange Act Rule 13a-15(f)
and 15d-15(f)) designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP and such internal control over financial reporting is effective. The Company
presented in its most recently filed annual report under the Exchange Act the conclusions of the certifying officers about the effectiveness
of the Company’s internal control over financial reporting based on their evaluations as of the end of the period covered by such
report. Since the Evaluation Date, there have been no significant changes in the Company’s internal control over financial reporting
or, to the Company’s knowledge, in other factors that could significantly affect the Company’s internal control over financial
reporting.

 

5.10         
Absence of Litigation. There is no claim, action, suit, arbitration, investigation or other proceeding pending against,
or to the knowledge of the Company and each Subsidiary, threatened against or affecting, the Company, any Subsidiary or any of the Company’s
or any Subsidiary’s properties or, to the knowledge of the Company and each Subsidiary, any of its respective officers or directors
before any Governmental Entity, in each case other than legal proceedings that are not reasonably expected to result in a Material Adverse
Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any action involving
a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty relating to the Company
or any Subsidiary. There has not been, and to the knowledge of the Company and each Subsidiary, there is not pending or contemplated,
any investigation by the Commission of the Company or any Subsidiary or any current or former director or officer of the Company or any
Subsidiary. The Company has not received any stop order or other order suspending the effectiveness of any registration statement filed
by the Company under the Exchange Act or the Securities Act and, to the Company’s knowledge, the Commission has not issued any such
order.

 

5.11         
Taxes. The Company and the Subsidiary have filed all U.S. and Canadian federal, and material state, provincial, municipal
and local and any other foreign tax returns that are required to be filed or have properly requested extensions thereof and have paid
all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against
any of them except as may be contested in good faith and by appropriate proceedings and except where the failure to file or pay would
not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. The Company has made adequate charges,
accruals and reserves in the applicable financial statements referred to in Section 5.8(b) above in respect of all U.S. and Canadian federal,
state, provincial, municipal, local and foreign taxes for all periods as to which the tax liability of the Company or the Subsidiary has
not been finally determined, except where the failure to make such adequate charge, accrual or reserve would not reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect.

 

    8 

     

    

 

		5.12	Compliance with Laws.

 

(a)              
 The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in,
or the results of which are referred to in, the SEC Reports were and, if still pending, are being conducted in all material respects in
accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific
research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents
the data derived from such studies, and the Company and the Subsidiary have no knowledge of any other studies the results of which are
inconsistent with, or otherwise call into question, the results described or referred to in the SEC Reports; the Company and the Subsidiary
have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department
of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory
agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither
the Company nor the Subsidiary has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension
or modification of any clinical trials that are described or referred to in the SEC Reports; and the Company and the Subsidiary have each
operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory
Agencies.

 

(b)              
To the Company’s knowledge, neither the Company nor any of its directors, officers, employees or agents, has made,
or caused the making of, any false statements on, or material omissions from, any other records or documentation prepared or maintained
to comply with the requirements of the FDA or any other Governmental Entity.

 

5.13         
Brokers. There is no investment banker, broker, finder, financial advisor, placement agent or other Person that has
been retained by or is authorized to act on behalf of the Company or any Subsidiary who might be entitled to any fee or commission in
connection with the transactions contemplated by this Agreement.

 

5.14          Environmental
Matters. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect: (i)
neither the Company nor the Subsidiary is in violation of any federal, state, provincial, local or foreign statute, law, rule,
regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any
judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment
(including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including,
without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants,
wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous
Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling
of Hazardous Materials (collectively, “Environmental Laws”); (ii) the Company and the Subsidiary have all
permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their
requirements; (iii) there are no pending or, to the Company’s knowledge, threatened administrative, regulatory or judicial
actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating
to any Environmental Law against the Company or the Subsidiary; and (iv) to the Company’s knowledge, there are no events or
circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or
proceeding by any private party or governmental body or agency, against or affecting the Company or the Subsidiary relating to
Hazardous Materials or any Environmental Laws.

 

    9 

     

    

 

5.15         
Intellectual Property Matters. To the knowledge of the Company, the Company owns, possesses, licenses or has other
rights to use, on reasonable terms, all patents, patent applications, trade and service marks, trade and service mark registrations, trade
names, copyrights, licenses, inventions, trade secrets, technology, know-how and other intellectual property (collectively, the “Intellectual
Property”) necessary for the conduct of the Company’s business as now conducted or as proposed in the SEC Reports
to be conducted (the “Company Intellectual Property”) except where the failure to have such Intellectual Property
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. To the Company’s knowledge:
(i) there are no third parties who have rights to any Intellectual Property that is disclosed in the SEC Reports; and (ii) there is no
infringement by third parties of any Intellectual Property. There is no pending or, to the Company’s knowledge, threatened action,
suit, proceeding or claim by others: (A) challenging the Company’s rights in or to any Intellectual Property, and the Company is
unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B) challenging the validity,
enforceability or scope of any material Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis
for any such action, suit, proceeding or claim; or (C) asserting that the Company or the Subsidiary infringes or otherwise violates, or
would, upon the commercialization of any product or service described in the SEC Reports as under development, infringe or violate, any
patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, and the Company is unaware
of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The product candidates described in the
SEC Reports as under development by the Company or the Subsidiary fall within the scope of the claims of one or more patents owned by,
or exclusively licensed to, the Company or the Subsidiary.

 

5.16          Absence
of Changes. Since the Evaluation Date: (a) there has not been any Material Adverse Effect or any event or events that
individually or in the aggregate would reasonably be expected to have a Material Adverse Effect; (b) there has not been any dividend
or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, (c) neither
the Company nor any Subsidiary has sustained any material loss or interference with the Company’s or any Subsidiary’s
business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or
dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, and (d) neither the
Company nor any Subsidiary has incurred any material liabilities except in the ordinary course of business.

 

5.17         
Suppliers and Customers. Neither the Company nor any Subsidiary has any knowledge of any termination, cancellation
or threatened termination or cancellation or limitation of, or any material dissatisfaction with, the business relationship between the
Company or any Subsidiary and any material supplier, customer, vendor, customer or client.

 

    10 

     

    

 

 

5.18          Application
of Takeover Protections. The Company and its Board of Directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company’s Charter Documents or the laws of its state of incorporation that
is or could become applicable to each Purchaser as a result of such Purchaser and the Company fulfilling their obligations or
exercising their rights under this Agreement, including without limitation as a result of the Company’s issuance of the
Pre-Funded Warrants and such Purchaser’s ownership of the Pre-Funded Warrants.

 

5.19          Foreign
Corrupt Practices. Since December 31, 2018, neither the Company nor the Subsidiary nor, to the Company’s knowledge, any
director, officer, agent, employee, Affiliate or other person acting on behalf of the Company or the Subsidiary has, in the course
of its actions for, or on behalf of, the Company or the Subsidiary (i) used any corporate funds for any unlawful contribution, gift,
entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any
domestic government official, “foreign official” (as defined in the U.S. Foreign Corrupt Practices Act of 1977, as
amended, and the rules and regulations thereunder (collectively, the “FCPA”)) or employee from corporate
funds; (iii) violated or is in violation of any provision of the FCPA or any applicable non-U.S. anti-bribery statute or regulation;
or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any domestic government
official, such foreign official or employee; and the Company and the Subsidiary and, to the Company’s knowledge, the
Company’s Affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain
policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance
therewith.

 

5.20         
Insurance. Each of the Company and its Subsidiaries are insured by recognized, financially sound and reputable institutions
with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their
businesses including, but not limited to, policies covering material real and personal property owned or leased by the Company and each
Subsidiary against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and the Subsidiary
for product liability claims and clinical trial liability claims. The Company has no reason to believe that it or the Subsidiary will
not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar
institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that could not be expected to have
a Material Adverse Effect. Neither the Company nor any Subsidiaries has been denied any insurance coverage which it has sought or for
which it has applied.

 

5.21         
No Manipulation of Shares. The Company has not taken, nor will it take, directly or indirectly, any action designed
to stabilize or manipulate the price of the Common Shares or any security of the Company to facilitate the sale or resale of any of the
Pre-Funded Warrants.

 

5.22          Disclosure.
The Company understands and confirms that the Purchasers will rely on the foregoing representations in effecting transactions in
securities of the Company. No representation or warranty by the Company contained in this Agreement contains any untrue statement of
a material fact or omits to state any material fact necessary in order to make the statements made therein, in light of the
circumstances under which they were made, not misleading. The Company acknowledges and agrees that the Purchasers do not make and
have not made any representations or warranties with respect to the transactions contemplated hereby other than those specifically
set forth in Section 4 hereof.

 

    11 

     

    

 

Section 6.                Covenants.

 

6.1            Reasonable Best Efforts. Each party shall use its reasonable best efforts to timely satisfy each of the conditions
to be satisfied by it as provided in Section 7 of this Agreement.

 

6.2            Reporting Status. During the Reporting Period, the Company shall use reasonable best efforts to: (a) timely file
all reports required to be filed with the Commission pursuant to the Exchange Act or the rules and regulations thereunder, and (b) not
take any action or file any document (whether or not permitted by the Securities Act or the rules promulgated thereunder) to terminate
or suspend the Company’s reporting and filing obligations under the Exchange Act or Securities Act.

 

6.3            Use
of Proceeds. The Company will use the proceeds from the sale of the Pre-Funded Warrants for general corporate purposes, research
and development, business development, working capital and general and administrative expenses.

 

6.4            Disclosure
of Transactions and Other Material Information. On or before 9:00 a.m., New York City time, on the Business Day following the date
of this Agreement, the Company shall file a Current Report on Form 8-K (or an amendment to a prior Current Report on Form 8-K) describing
the terms and conditions of the transactions contemplated by the Transaction Documents in the form required by the Exchange Act and attaching
the Agreement as an exhibit to such filing (including all attachments, the “8-K Filing”) in each case, to the
extent not previously disclosed on a Current Report on Form 8-K. The Company shall not publicly disclose the name of any Purchaser or
any Affiliate or investment adviser of the Purchaser, or include the name of any Purchaser or any Affiliate or investment adviser of
the Purchaser in any filing with the Commission (other than in a Registration Statement and any exhibits to filings made in respect of
this transaction in accordance with periodic report or current report filing requirements under the Exchange Act) or any regulatory agency,
without the prior written consent of such Purchaser, except to the extent such disclosure is required by law or regulations, in which
case the Company shall provide each Purchaser whose name is to be disclosed with prior notice of such disclosure and a reasonable opportunity
to comment on the proposed disclosure insofar as it relates specifically to such Purchaser. Subject to the foregoing, neither the Company
nor the Purchasers shall issue any press releases or any other public statements with respect to the transactions contemplated hereby
without the prior written consent of the other party, such consent not to be unreasonably withheld or delayed.

 

6.5            Expenses.
The Company and each Purchaser is liable for, and will pay, its own expenses incurred in connection with the negotiation, preparation,
execution and delivery of this Agreement, including, without limitation, attorneys’ and consultants’ fees and expenses.

 

    12 

     

    

 

Section 7.                Conditions
of Parties’ Obligations.

 

7.1            Conditions
of the Purchasers’ Obligations at the Closing. The obligations of the Purchasers under Section 2 hereof are subject to the
fulfillment, prior to the Closing, of all of the following applicable conditions, any of which may be waived in whole or in part by the
Purchasers in their absolute discretion. If the following conditions are not satisfied on or before 5:00 p.m. (Eastern Time) on the tenth
Business Day following the Effective Date (the “Outside Date”), then the Purchasers may terminate this Agreement
upon providing written notice to the Company.

 

(a)              
Representations and Warranties. The representations and warranties of the Company contained in this Agreement and
in any certificate, if any, or other writing, if any, delivered by the Company pursuant hereto shall be true and correct in all material
respects on and as of the Closing Date with the same effect as though such representations and warranties had been made on and as of the
Closing Date (except to the extent expressly made as of an earlier date in which case as of such earlier date).

 

(b)              
Performance. The Company shall have performed and complied in all material respects with all covenants, agreements,
obligations and conditions contained in this Agreement that are required to be performed or complied by it on or prior to the Closing
Date.

 

(c)              
Delivery. The Company shall deliver this Agreement duly executed by the Company.

 

(d)              
Qualification under State Securities Laws. All registrations, qualifications, permits and approvals, if any, required
under applicable state securities laws shall have been obtained for the lawful execution, delivery and performance of this Agreement.

 

(e)              
Consents and Waivers. The Company shall have obtained all consents or waivers necessary to execute and perform its
obligations under this Agreement. All corporate and other action and governmental filings necessary for the Company to effectuate the
terms of this Agreement and other agreements and instruments executed and delivered by the Company in connection herewith shall have been
made or taken by the Company, and no Material Adverse Effect has occurred with respect to the operation of the Company’s business.

 

(f)               
Absence of Litigation. No proceeding challenging this Agreement or the transactions contemplated hereby, or seeking
to prohibit, alter, prevent or materially delay the Closing, shall have been instituted or be pending before any court, arbitrator, governmental
body, agency or official. The sale of the Pre-Funded Warrants by the Company shall not be prohibited by any law or governmental order
or regulation.

 

7.2            Conditions
of the Company’s Obligations. The Company’s obligations under Section 2 hereof are subject to the fulfillment prior to
or on the Closing Date of all of the following conditions, any of which may be waived in whole or in part by the Company: (a) each Purchaser
at the Closing shall have performed all of its obligations hereunder required to be performed by it at or prior to the Closing, and (b)
the representations and warranties of the Purchasers at the Closing contained in this Agreement shall be true and correct at and as of
the Closing as if made at and as of the Closing (except to the extent expressly made as of an earlier date, in which case as of such
earlier date). If the foregoing conditions are not satisfied on or the Outside Date, then the Company may terminate this Agreement upon
providing written notice to the Purchasers.

 

    13 

     

    

 

Section
8. Transfer Restrictions; Restrictive Legend. The Purchasers understand that the Company may, as a condition to the
transfer of any of the Pre-Funded Warrants or Warrant Shares, require that the request for transfer be accompanied by an opinion of counsel
reasonably satisfactory to the Company, to the effect that the proposed transfer does not result in a violation of the Securities Act,
unless such transfer is covered by an effective registration statement or by Rule 144 or Rule 144A under the Securities Act; provided,
however, that an opinion of counsel shall not be required for a transfer: (A) to its partners or former partners in accordance with partnership
interests, (B) to any Affiliate or other Person under common management with such Purchaser, or (C) a transfer that is made pursuant to
a bona fide gift to a third party; provided, further, that (i) the transferee in each case agrees to be subject to the restrictions in
this Section 8 and provides the Company with a representation letter containing customary investment representations under the Securities
Act, (ii) the Company reasonably satisfies itself that the number of transferees is sufficiently limited and (iii) in the case of transferees
that are partners or limited liability company members, the transfer is for no consideration. It is understood that the certificates evidencing
the Pre-Funded Warrants or the book-entry registrations for the Warrant Shares may bear substantially the following legends:

 

	8.1	“THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933
OR ANY APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION
STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL SATISFACTORY
TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A OF SUCH ACT.”

 

and

 

“UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE SEPTEMBER          , 2021.”

 

Section 9.                Registration,
Transfer and Substitution of Warrants.

 

9.1            Register;
Ownership of Pre-Funded Warrants. The Company will keep at its principal office, or will cause its transfer agent to keep, a register
in which the Company will provide for the registration of transfers of the Pre-Funded Warrants. The Company may treat the Person in whose
name any of the Pre-Funded Warrants are registered on such register as the owner thereof and the Company shall not be affected by any
notice to the contrary. All references in this Agreement to a “holder” of any Warrants shall mean the Person in whose name
such Warrants are at the time registered on such register.

 

    14 

     

    

 

9.2            Replacement of Pre-Funded Warrants. Upon receipt of evidence reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of any certificate representing any of the Pre-Funded Warrants, and, in the case of any such loss, theft
or destruction, upon delivery of an indemnity agreement and surety bond reasonably satisfactory to the Company or, in the case of any
such mutilation, upon surrender of such certificate for cancellation at the office of the Company maintained pursuant to Section 9.1
hereof, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant representing such Warrants, of like tenor.

 

Section 10.              Registration
Rights.

 

10.1         
Mandatory Registration. The Company shall prepare, and, as soon as practicable but in no event later than 30 days
after the Closing Date (the “Filing Deadline”), file with the Commission a Registration Statement under the
Securities Act on appropriate form covering the resale of the full amount of the Registrable Securities. The Company shall use its commercially
reasonable efforts to have the Registration Statement declared effective by the Commission as soon as practicable, but in no event later
than the date (the “Effectiveness Deadline”), which shall be either: (i) in the event that the Commission does
not review the Registration Statement, 90 days after the Closing Date, or (ii) in the event that the Commission reviews the Registration
Statement, 120 days after the Closing Date (but in any event, no later than five Business Days following the Commission indicating that
it has no further comments on the Registration Statement). Subject to any comments from the staff of the Commission (the “Staff”),
such Registration Statement shall include the plan of distribution attached hereto as Exhibit B; provided, however, that no Purchaser
shall be named as an “underwriter” in the Registration Statement without the Purchaser’s prior written consent. Such
Registration Statement shall not include any securities for the account of any other holder without the prior written consent of the Purchasers.

 

10.2         
Rule 415; Cutback. If at any time the Staff takes the position that the offering of some or all of the Registrable
Securities in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under
the Securities Act or requires any Purchaser to be named as an “underwriter,” the Company shall use its reasonable best efforts
to persuade the Commission that the offering contemplated by the Registration Statement is a valid secondary offering and not an offering
“by or on behalf of the issuer” as defined in Rule 415 and that none of the Purchasers is an “underwriter.” In
the event that, despite the Company’s reasonable best efforts and compliance with the terms of this Section 10.2, the Staff refuses
to alter its position, the Company shall (i) remove from the Registration Statement such portion of the Registrable Securities (the “Cut
Back Securities”) and/or (ii) agree to such restrictions and limitations on the registration and resale of the Registrable
Securities as the Staff may require to assure the Company’s compliance with the requirements of Rule 415 (collectively, the “SEC
Restrictions”); provided, however, that the Company shall not agree to name any Purchaser as an “underwriter”
in such Registration Statement without the prior written consent of such Purchaser. Any cutback imposed on the Purchasers pursuant to
this Section 10.2 shall be allocated among the Purchasers on a pro rata basis, unless the SEC Restrictions otherwise require or provide
or the Purchasers otherwise agree.

    15 

     

    

 

 10.3 Obligations of the Purchasers.

 

(a)              
At least ten Business Days prior to the first anticipated filing date of the Registration Statement, the Company shall notify
each Purchaser in writing of any information the Company requires from such Purchaser in order to have that Purchaser’s Registrable
Securities included in such Registration Statement. It shall be a condition precedent to the obligations of the Company to complete the
registration pursuant to this Agreement with respect to the Registrable Securities of a particular Purchaser that the Purchaser shall
furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition
of the Registrable Securities held by it as shall be reasonably required to effect the effectiveness of the registration of such Registrable
Securities and shall execute such documents in connection with such registration as the Company may reasonably request.

 

(b)              
Each Purchaser, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested
by the Company in connection with the preparation and filing of any Registration Statement hereunder, unless the Purchaser has notified
the Company in writing of the Purchaser’s election to exclude all of the Purchaser’s Registrable Securities from such Registration
Statement.

 

(c)              
Each Purchaser agrees that, upon receipt of any notice from the Company of the issuance of any stop order or other suspension
of effectiveness of a Registration Statement, or the suspension of the qualification of any of the Registrable Securities for sale in
any jurisdiction or the happening of any event, as a result of which the prospectus included in a Registration Statement, as then in effect,
includes an untrue statement of a material fact or omission to state a material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under which they were made, not misleading, the Purchaser will immediately discontinue
disposition of Registrable Securities pursuant to any Registration Statement(s) covering such Registrable Securities until the Purchaser’s
receipt of the copies of the supplemented or amended prospectus or receipt of notice that no supplement or amendment is required.

 

(d)              
Each Purchaser covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act
as applicable to it or an exemption therefrom in connection with sales of Registrable Securities pursuant to the Registration Statement.

 

10.4         
Expenses of Registration. All reasonable expenses incurred in connection with registrations, filings or qualifications
pursuant to this Section 10, including, without limitation, all registration, listing and qualifications fees, printers and accounting
fees, and fees and disbursements of counsel for the Company, shall be paid by the Company. Notwithstanding the foregoing, in no event
shall the Company be responsible for underwriting discounts, commissions, placement agent fees or other similar expenses payable with
respect to Registrable Securities being sold or offered for sale by the Purchasers.

 

    16 

     

    

 

10.5          Reports
under the Exchange Act. With a view to making available to the Purchasers the benefits of Rule 144 promulgated under the
Securities Act or any other similar rule or regulation of the Commission that may at any time permit the Purchasers to sell
securities of the Company to the public without registration (“Rule 144”), the Company agrees to:

 

(a)              
make and keep public information available, as those terms are understood and defined in Rule 144, during the Reporting
Period; and

 

(b)              
file with the Commission in a timely manner all reports and other documents required of the Company under the Exchange Act.

 

Section
11. Definitions. Unless the context otherwise requires, the terms defined in this Section 11 shall have the meanings
specified for all purposes of this Agreement. All accounting terms used in this Agreement, whether or not defined in this Section 11,
shall be construed in accordance with GAAP. If the Company has one or more Subsidiaries, such accounting terms shall be determined on
a consolidated basis for the Company and each of its Subsidiaries, and the financial statements and other financial information to be
furnished by the Company pursuant to this Agreement shall be consolidated and presented with consolidating financial statements of the
Company and each of its Subsidiaries.

 

“Affiliate”
shall have the meaning ascribed to such term in Rule 12b-2 of the General Rules and Regulations under the Exchange Act.

 

“Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed.

 

“Effectiveness
Date” means the date the Registration Statement pursuant to Section 10 has been declared effective by the Commission.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended.

 

“GAAP” means U.S. generally accepted accounting principles
consistently applied.

 

“Governmental
Entity” means any national, federal, state, municipal, local, territorial, foreign or other government or any department,
commission, board, bureau, agency, regulatory authority, self-regulatory organization or instrumentality thereof, or any court, judicial,
administrative or arbitral body or public or private tribunal.

 

“Knowledge”
by a Person of a particular fact or other matter means the following: (a) if the Person is an individual, that such individual is actually
aware or reasonably should be aware, after due inquiry, by virtue of such person’s office, of such fact or other matter; and (b)
if the Person is an entity, that any executive officer of such Person is actually aware or reasonably should be aware, after due inquiry,
of such fact or other matter.

 

“Material
Adverse Effect” means any (i) adverse effect on the reservation, issuance, delivery or validity of the Pre-Funded Warrants,
as applicable, or the transactions contemplated hereby or on the ability of the Company to perform its obligations under this Agreement,
or (ii) material adverse effect on the condition (financial or otherwise), prospects, properties, assets, liabilities, business or operations
of the Company or any of its Subsidiaries.

 

    17 

     

    

 

“Person”
means and includes all natural persons, corporations, business trusts, associations, companies, partnerships, joint ventures, limited
liability companies and other entities and governments and agencies and political subdivisions.

 

“Pro
Rata Interest” means the number of Pre-Funded Warrants purchased by each Purchaser, relative to the total number of Pre-Funded
Warrants being sold hereunder, as reflected on Schedule I attached hereto.

 

“Registrable
Securities” means the Warrant Shares (including any equity securities of the Company that may be issued or distributed in
respect thereof by way of dividend or split or other distribution, recapitalization or reclassification). Registrable Securities will
cease to be Registrable Securities upon the earliest to occur of (i) a registration statement with respect to the resale by the Purchasers
of such securities has become effective under the Securities Act or the comparable statute of any applicable jurisdiction and such securities
have been disposed of in accordance with such registration statement, (ii) such securities have been sold or otherwise transferred or
assigned pursuant to Rule 144 (or any successor provision) under the Securities Act or another available exemption from the registration
requirements of the Securities Act, or (iii) all of such securities may be sold pursuant to Rule 144 during any ninety (90) day period.

 

“Registration
Statement” means a registration statement or registration statements of the Company filed under the Securities Act pursuant
to Section 10 hereof.

 

“Reporting
Period” means the period commencing on the Closing Date and ending on the earliest of: (i) the date as of which the Purchasers
may sell all of the Warrant Shares under Rule 144 without volume or manner-of-sale restrictions and without the requirement for the Company
to be in compliance with the current public information requirements under Rule 144(c)(1) (or any successor thereto) promulgated under
the Securities Act; and (ii) the date on which such Purchaser shall have sold all of the Warrant Shares pursuant to a registration statement.

 

“Subsidiary”
means any corporation, association trust, limited liability company, partnership, joint venture or other business association or entity,
at least 50% of the outstanding voting securities of which are at the time owned or controlled directly or indirectly by the Company.

 

“Trading
Day” means any day on which the Common Shares is traded on the Trading Market; provided that “Trading Day” shall
not include any day on which the Common Shares are scheduled to trade on such exchange or market for less than 4.5 hours or any day that
the Common Shares are suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market
does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New
York time).

 

“Trading
Market” means the following markets or exchanges on which the Common Shares are listed or quoted for trading on the date
in question: NYSE Amex Equities, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange or the OTC Markets Group Inc.

 

    18 

     

    

 

“Transaction
Documents” means this Agreement and all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated hereunder.

 

Section 12.              Miscellaneous.

 

12.1         
Waivers and Amendments. Upon the approval of the Company and the written consent of the Purchasers, the obligations
of the Company and the rights of the Purchasers under this Agreement may be waived (either generally or in a particular instance, either
retroactively or prospectively and either for a specified period of time or indefinitely). Neither this Agreement, nor any provision hereof,
may be changed, waived, discharged or terminated orally or by course of dealing, but only by an instrument in writing executed by the
Company and the Purchasers.

 

12.2         
Notices. All notices, requests, consents, and other communications under this Agreement shall be in writing and shall
be deemed delivered: (a) when delivered, if delivered personally, (b) four Business Days after being sent by registered or certified mail,
return receipt requested, postage prepaid, (c) one Business Day after being sent via a reputable nationwide overnight courier service
guaranteeing next Business Day delivery, or (d) when receipt is acknowledged, in the case of email, in each case to the intended recipient
as set forth below, with respect to the Company, and to the addresses set forth on the signature pages hereto, with respect to the Purchasers.

 

If to the Company:               Attn: Amit Hasija, Chief Financial Officer

Milestone Pharmaceuticals Inc.

1111 Dr. Frederik-Philips Blvd., Suite 420 Montréal,
Québec H4M 2X6

Email: ahasija@milestonepharma.com

 

with copies (which shall not constitute notice) to:

 

Attn: Ryan Sansom

 Cooley LLP

500 Boylston Street, 14th Floor Boston,
MA 02116

Email: rsansom@cooley.com

 

or at such other address as the Company or each Purchaser
may specify by written notice to the other parties hereto in accordance with this Section 12.2.

 

12.3         
Cumulative Remedies. None of the rights, powers or remedies conferred upon the Purchasers on the one hand or the
Company on the other hand shall be mutually exclusive, and each such right, power or remedy shall be cumulative and in addition to every
other right, power or remedy, whether conferred by this Agreement or now or hereafter available at law, in equity, by statute or otherwise.

 

    19 

     

    

 

12.4         
Successors and Assigns. All the terms and provisions of this Agreement shall be binding upon and inure to the benefit
of and be enforceable by the respective parties hereto, the successors and permitted assigns of each Purchaser and the successors of
the Company, whether so expressed or not. None of the parties hereto may assign its rights or obligations hereof without the prior written
consent of the Company, except that a Purchaser may, without the prior consent of the Company, assign its rights to purchase the Pre-Funded
Warrants hereunder to any of its Affiliates (provided each such Affiliate agrees to be bound by the terms of this Agreement and makes
the same representations and warranties set forth in Section 4 hereof). This Agreement shall not inure to the benefit of or be enforceable
by any other Person.

 

12.5         
Headings. The headings of the Sections and paragraphs of this Agreement have been inserted for convenience of reference
only and do not constitute a part of this Agreement.

 

12.6         
Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the
State of New York without regard to its conflict of law principles. Any suit, action or proceeding seeking to enforce any provision of,
or based on any matter. Any action, suit or proceeding arising out of or in connection with, Agreement or the transactions contemplated
hereby may be brought in any federal or state court located in the City of New York and State of New York, and each of the Parties hereby
consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding
and irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of the
venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding which is brought in any such
court has been brought in an inconvenient forum. Process in any such suit, action or proceeding may be served on any party anywhere in
the world, whether within or without the jurisdiction of any such court. The Company has the power to submit, and pursuant to this Agreement
has, to the extent permitted by law, legally, validly, effectively and irrevocably submitted, to the jurisdiction of the courts herein
described.

 

12.7         
Counterparts; Effectiveness. This Agreement may be executed in any number of counterparts and by different parties
hereto in separate counterparts, with the same effect as if all parties had signed the same document. All such counterparts (including
counterparts delivered by facsimile or other electronic format) shall be deemed an original, shall be construed together and shall constitute
one and the same instrument. This Agreement shall become effective when each party hereto shall have received counterparts hereof signed
by all of the other parties hereto.

 

12.8         
Entire Agreement. This Agreement contains the entire agreement among the parties hereto with respect to the subject
matter hereof and thereof and, except as set forth below, this agreement supersedes and replaces all other prior agreements, written or
oral, among the parties hereto with respect to the subject matter hereof and thereof. Notwithstanding the foregoing, this Agreement shall
not supersede any confidentiality or other non-disclosure agreements that may be in place between the Company and any Purchaser.

 

12.9          Severability.
If any provision of this Agreement shall be found by any court of competent jurisdiction to be invalid or unenforceable, the parties
hereby waive such provision to the extent that it is found to be invalid or unenforceable. Such provision shall, to the maximum extent
allowable by law, be modified by such court so that it becomes enforceable, and, as modified, shall be enforced as any other provision
hereof, all the other provisions hereof continuing in full force and effect.

 

*      *      *

 

    20 

     

    

 

 

IN WITNESS WHEREOF, the parties hereto
have caused this Securities Purchase Agreement to be duly executed as of the Effective Date.

 

	 	THE COMPANY:
	 
	 	MILESTONE PHARMACEUTICALS INC.
	 	 
	
	 	By:	/s/ Joseph Oliveto
	 	 	Name: Joseph Oliveto
	 	 	Title: President and CEO

 

     

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed as of the Effective Date.

 

	 	PURCHASERS:
	 
	 	RTW MASTER FUND, LTD.
	  
	 	By:	/s/ Roderick Wong
	 	 	Name: Roderick Wong
	 	 	Title: Director
	 
	 	RTW INNOVATION MASTER FUND, LTD.
	 
	 	By:	/s/ Roderick Wong
	 	 	Name: Roderick Wong
	 	 	Title: Director
	 
	 	RTW VENTURE FUND LIMITED
	 
		By: RTW Investments, LP, its Investment Manager 
	 	 
	 	By:	/s/ Roderick Wong
	 	 	Name: Roderick Wong
	 	 	Title: Managing Partner
	 
	

     

     

    

 

SCHEDULE
I

 

	Purchaser Name	 	No. of  Pre-

                                                                                Funded 
Warrants
	 	 	Aggregate Purchase Price	 
	RTW MASTER FUND, LTD., a company
 existing under the laws of the Cayman Islands, having its head office at 190 Elgin Avenue, George Town, Grand Cayman KY1-9005, Cayman Islands, represented herein by its Director, Roderick Wong.
	 	587,721	 	$	3,220,711.08	 
	RTW INNOVATION MASTER FUND,
 LTD., a company existing under the laws of the Cayman Islands, having its head office at 190 Elgin Avenue, George Town, Grand Cayman KY1-9005, Cayman Islands, represented herein by its Director, Roderick Wong.
	 	259,150	 	$	1,420,142.00	 
	RTW VENTURE FUND LIMITED, a
 company existing under the laws of Guernsey, having its head office at P.O. Box 286, Floor 2, Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 4LY, represented herein by the Managing Partner of its Investment Manager, Roderick Wong.
	 	63,875	 	$	350,035.00	 

 

 

 

 

     

     

    

 

EXHIBIT A

 

FORM OF PRE-FUNDED WARRANT

 

     

     

    

 

SCHEDULE 1

 

FORM OF EXERCISE NOTICE

 

[To be executed by the Holder to purchase
Common Shares under the Warrant]

 

Ladies and Gentlemen:

 

(1) 
The undersigned is the Holder of Warrant No.      (the “Warrant”) issued
by Milestone Pharmaceuticals Inc., an exempted company incorporated and existing under the laws of the Province of Québec, Canada
(the “Company”). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in
the Warrant.

 

(2) The undersigned hereby exercises
its right to purchase                   Warrant
Shares pursuant to the Warrant.

 

(3) 
Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms
of the Warrant. If permissible, the Warrant Shares shall be delivered to the following DWAC Account Number:

 

 

 

 

 

(4) 
By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise
evidenced hereby the Holder will not beneficially own in excess of the number of Common Shares (as determined in accordance with Section
13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice
relates.

 

(5) 
The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933,
as amended.

 

	Dated:	 	 
	 
	Name of Holder:	 	 
	 
	By:	 	 
	 
	Name:	 	 
	 
	Title:  	 	 

 

(Signature must conform in all respects to name of Holder
as specified on the face of the Warrant)

 

     

     

    

 

EXHIBIT B

 

PLAN OF DISTRIBUTION

 

The selling
shareholders, which shall include donees, pledgees, transferees or other successors-in-interest selling warrant shares or interests in
warrant shares received after the date of this prospectus from a selling shareholders as a gift, pledge, partnership distribution or other
transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their warrant shares or interests in warrant shares
on any stock exchange, market or trading facility on which the warrant shares are traded or in private transactions. These dispositions
may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying
prices determined at the time of sale, or at negotiated prices.

 

The selling shareholders may use
any one or more of the following methods when disposing of warrant shares or interests therein:

 

		·	ordinary brokerage transactions and transactions in which the broker-dealer solicits
purchasers;
	 	 	 

		·	block trades in which the broker-dealer will attempt to sell the warrant shares
as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
	 	 	 

		·	purchases by a broker-dealer as principal and resale by the broker-dealer for
its own account;
	 	 	 

		·	an exchange distribution in accordance with the rules of the applicable exchange;
	 	 	 

		·	privately negotiated transactions;
	 	 	 

		·	short sales effected after the date the registration statement of which this prospectus
is a part is declared effective by the SEC;
	 	 	 

		·	through the writing or settlement of options or other hedging transactions, whether
through an options exchange or otherwise;
	 	 	 

		·	through agreements between broker-dealers and the selling shareholders to sell a
specified number of such warrant shares at a stipulated price per share;
	 	 	 

		·	a combination of any such methods of sale; and
	 	 	 

		·	any other method permitted by applicable law.

 

The selling
shareholders may, from time to time, pledge or grant a security interest in some or all of the warrant shares by them and, if they default
in the performance of their secured obligations, the pledgees or secured parties may offer and sell the warrant shares, from time to time,
under this prospectus, or under an amendment to this prospectus under Rule 424(b) or other applicable provision of the Securities Act
amending the list of selling shareholders to include the pledgee, transferee or other successors in interest as selling shareholders under
this prospectus. The selling shareholders also may transfer the warrant shares in other circumstances, in which case the pledgees, transferees
or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

 

In connection with the sale of warrant shares
or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the warrant shares in the course of hedging the positions they assume. The
selling shareholders may also sell our common shares short and deliver these securities to close out their short positions, or loan
or pledge the warrant shares to broker-dealers that in turn may sell these securities. The selling shareholders may also enter into
options or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative
securities that require the delivery to each such broker-dealer or other financial institution of warrant shares offered by this
prospectus, which warrant shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as
supplemented or amended to reflect such transaction).

 

     

     

    

 

The aggregate
proceeds to the selling shareholders from the sale of the warrant shares offered by them will be the purchase price of the warrant shares
less discounts or commissions, if any. Each of the selling shareholders reserves the right to accept and, together with its agents from
time to time, to reject, in whole or in part, any proposed purchase of warrant shares to be made directly or through agents. We will not
receive any of the proceeds from the sale of warrant shares in this offering, although we will receive the nominal exercise price upon
exercise of the pre- funded warrants for the warrant shares, if such warrants are exercised for cash.

 

The selling
shareholders also may resell all or a portion of the warrant shares in open market transactions in reliance upon Rule 144 under the Securities
Act of 1933, provided that they meet the criteria and conform to the requirements of that rule.

 

The selling
shareholders and any underwriters, broker-dealers or agents that participate in the sale of the warrant shares or interests therein may
be “underwriters” within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit
they earn on any resale of the warrant shares may be underwriting discounts and commissions under the Securities Act. Selling shareholders
who are “underwriters” within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery
requirements of the Securities Act.

 

To the extent
required, the warrant shares to be sold, the names of the selling shareholders, the respective purchase prices and public offering prices,
the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be
set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes
this prospectus.

 

In order to
comply with the securities laws of some states, if applicable, the warrant shares may be sold in these jurisdictions only through registered
or licensed brokers or dealers. In addition, in some states the warrant shares may not be sold unless it has been registered or qualified
for sale or an exemption from registration or qualification requirements is available and is complied with.

 

We have advised the
selling shareholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of warrant shares in
the market and to the activities of the selling shareholders and their affiliates. In addition, to the extent applicable we will
make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling shareholders for
the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling shareholders may indemnify any
broker-dealer that participates in transactions involving the sale of the warrant shares against certain liabilities, including
liabilities arising under the Securities Act.

 

* * *Exhibit 10.2

 

 

NEITHER THIS SECURITY NOR THE SECURITIES
FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF
ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

UNLESS PERMITTED UNDER
SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE SEPTEMBER [ • ], 2021.

 

MILESTONE PHARMACEUTICALS
INC.

 

FORM OF PRE-FUNDED WARRANT
TO PURCHASE COMMON SHARES

 

Number of Shares: [ • ] (subject to adjustment)

 

	Warrant No. PFW2021 - [ ]	Original Issue Date: May [ • ], 2021

 

Milestone Pharmaceuticals
Inc., an exempted company incorporated and existing under the laws of the Province of Québec, Canada (the “Company”),
hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [                                        ]
or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the
Company up to a total of [ • ] common shares, no par value per share (the “Common Shares”), of the Company (each such
share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price per share
equal to $0.01 per share (as adjusted from time to time as provided in Section 9 herein, the “Exercise Price”) upon
surrender of this Warrant to Purchase Common Shares (including any Warrants to Purchase Common Shares issued in exchange, transfer or
replacement hereof, the “Warrant”) at any time and from time to time on or after the date hereof (the “Original
Issue Date”) until the Warrant has been exercised in full, subject to the following terms and conditions:

1.  Definitions. For purposes of
this Warrant, the following terms shall have the following meanings:

 

(a) 
“Affiliate” means any Person directly or indirectly controlled by, controlling or under common control with,
a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall
continue.

 

 (b)  “Commission” means the United States Securities and Exchange Commission.

 

(c) 
“Closing Sale Price” means, for any security as of any date, the last trade price for such security on the
Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on
an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New
York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other
trading market on the relevant date, the last quoted bid price for the security in the over-the-counter market on the relevant date as
reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing
Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security
on such date shall be the fair market value as mutually determined in good faith by the Company and the Holder. All such determinations
shall be appropriately adjusted for any share dividend, share split, share combination or other similar transaction during the applicable
calculation period.

 

(d)  “Principal
Trading Market” means the national securities exchange or other trading market on which the Common Shares are primarily
listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market.

 

     

     

    

 

(e)  “Securities Act” means the Securities Act of 1933, as amended.

 

(f) 
“Trading Day” means any weekday on which the Principal Trading Market is open for trading. If the Common Shares
are not listed or admitted for trading, “Trading Day” means any day except any Saturday, any Sunday, any day which is a federal
legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other
governmental action to close.

 

(g) 
“Transfer Agent” means Computershare Investor Services Inc. and Computershare Trust Company, N.A., collectively,
the Company’s transfer agent and registrar for the Common Share, and any successor appointed in such capacity.

 

2. 
Warrant Register. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for
that purpose (the “Warrant Register”), in the name of the record Holder (which shall include the initial Holder or,
as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for
all other purposes, absent actual notice to the contrary.

 

3.   Registration
of Transfers. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to,
register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for
all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Shares in
substantially the form of this Warrant (any such new warrant, a “New Warrant”) evidencing the portion of this
Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so
transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall
be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has
in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the
Company’s own expense any New Warrant under this Section 3. Until due presentment for registration of transfer, the Company
may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice
to the contrary.

 

 4.  Exercise and Duration of Warrants.

 

(a) 
All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in Section 4(b) at any time
and from time to time on or after the Original Issue Date subject to the limitations set forth in Section 11.

 

(b) 
The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1 hereto
(the “Exercise Notice”), completed and duly signed, and (ii) payment of the Exercise Price (if applicable) in cash
or immediately available funds (or pursuant to cashless exercise provisions in accordance herewith and with Section 10) for the number
of Warrant Shares as to which this Warrant is being exercised. The date on which such Exercise Notice is delivered to the Company (as
determined in accordance with the notice provisions hereof) is an “Exercise Date.” The Holder shall not be required
to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the
same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number
of Warrant Shares, if any. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the
provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

 5.  Delivery of Warrant Shares.

 

(a)  The
Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the
account of the Holder’s or its designee’s balance account with The Depository Trust Company (“DTC”)
through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such
system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the
Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by issuing such Warrant Shares in the
name of the Holder or its designee in restricted book-entry form in the Company’s share register, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise by the date that is two (2) Trading Days after the delivery to the
Company of the Notice of Exercise and delivery of the aggregate Exercise Price (if applicable) to the Company. The Holder, or any
natural person or legal entity (each, a “Person”) so designated by the Holder to receive Warrant Shares, shall be
deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant
Shares are credited to the Holder’s DTC account or the date of restricted book-entry evidencing such Warrant Shares, as the
case may be.

 

     

     

    

 

(b) 
If by the close of the second (2nd) Trading Day after the Exercise Date, the Company fails to deliver to the Holder the required
number of Warrant Shares in the manner required pursuant to Section 5(a) or fails to credit the Holder’s DTC account for
such number of Warrant Shares to which the Holder is entitled, and if after such third (3rd) Trading Day and prior to the receipt of such
Warrant Shares, the Holder purchases (in an open market transaction or otherwise) Common Shares to deliver in satisfaction of a sale by
the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company
shall, within two (2) Trading Days after the Holder’s request promptly honor its obligation to deliver to the Holder such Warrant
Shares and pay cash to the Holder in an amount equal to the excess (if any) of Holder’s total purchase price (including brokerage
commissions, if any) for the Common Shares so purchased in the Buy-In less the product of (A) the number of Common Shares purchased in
the Buy-In, times (B) the Closing Sale Price of a Common Share on the Exercise Date.

 

(c) 
To the extent permitted by law and subject to Section 5(b), the Company’s obligations to issue and deliver Warrant Shares
in accordance with and subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional,
irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof,
the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation
or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or
alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such
obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section 5(b), nothing herein shall
limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver Common Shares
upon exercise of the Warrant as required pursuant to the terms hereof.

 

6. 
Charges, Taxes and Expenses. Issuance and delivery of Common Shares upon exercise of this Warrant shall be made without
charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp
duties) in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Company; provided, however,
that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any
Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all
other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

 

7. 
Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be
issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant,
but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each
case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances
shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company
may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated
Warrant to the Company as a condition precedent to the Company’s obligation to issue the New Warrant.

 

8. 
No Pre-Emptive Rights; Duly Issued Warrant Shares. The Company covenants that all Warrant Shares issuable and deliverable
upon exercise in full of this Warrant shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms
hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably
necessary to assure that such Common Shares may be issued as provided herein without violation of any applicable law or regulation, or
of any requirements of any securities exchange or automated quotation system upon which the Common Shares may be listed.

 

     

     

    

 

9. Certain Adjustments. The Exercise
Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth
in this Section 9.

 

(a) 
Share Dividends and Splits. If the Company, at any time while this Warrant is issued and outstanding, (i) pays a share dividend
on its Common Shares or otherwise makes a distribution on any class of capital shares issued and outstanding on the Original Issue Date
and in accordance with the terms of such shares on the Original Issue Date or as amended, that is payable in Common Shares, (ii) subdivides
its issued and outstanding Common Shares into a larger number of Common Shares, (iii) combines its issued and outstanding Common Shares
into a smaller number of Common Shares or (iv) issues by reclassification of capital shares any additional Common Shares of the Company,
then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of Common Shares
issued and outstanding immediately before such event and the denominator of which shall be the number of Common Shares issued and outstanding
immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the
record date for the determination of shareholders entitled to receive such dividend or distribution, provided, however, that if such record
date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly
as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the
time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately
after the effective date of such subdivision or combination.

 

(b) 
Pro Rata Distributions. If the Company, at any time while this Warrant is issued and outstanding, distributes to all holders
of Common Shares for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Shares
covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset
(in each case, a “Distribution”), other than a reclassification as to which Section 9(c) applies, then in each such
case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein
if the Holder had held the number of Common Shares acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the ownership limitation set forth in Section 11(a) hereof) immediately before the date
of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Shares
are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder’s right to participate
in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof, then the Holder
shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Shares as a result
of such Distribution to such extent)) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
the earlier of (i) such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership
limitation set forth in Section 11(a) hereof and (ii) such time as the Holder has exercised this Warrant.

 

(c)  Fundamental
Transactions. If, at any time while this Warrant is issued and outstanding (i) the Company effects any amalgamation, merger or
consolidation of the Company with or into another Person, in which the Company is not the surviving entity and in which the
shareholders of the Company immediately prior to such amalgamation, merger or consolidation do not own, directly or indirectly, at
least 50% of the voting power of the surviving entity immediately after such amalgamation, merger or consolidation, (ii) the Company
effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions,
(iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of share capital tender
shares representing more than 50% of the voting power of the capital shares of the Company and the Company or such other Person, as
applicable, accepts such tender for payment, (iv) the Company consummates a share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby
such other Person acquires more than the 50% of the voting power of the capital shares of the Company (except for any such
transaction in which the shareholders of the Company immediately prior to such transaction maintain, in substantially the same
proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of
the Common Shares or any compulsory share exchange pursuant to which the Common Shares are effectively converted into or exchanged
for other securities, cash or property (other than as a result of a subdivision or combination of Common Shares covered by Section
9(a) above) (in any such case, a “Fundamental Transaction”), then following such Fundamental Transaction the
Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as
it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such
Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without
regard to any limitations on exercise contained herein (the “Alternate Consideration”). The Company shall not
effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes
securities of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous
“cashless exercise” of this Warrant pursuant to Section 10 below or (ii) prior to or simultaneously with the
consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the
Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing
provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph
(c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type.

 

     

     

    

 

(d)  
Number of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to Section 9 (including any
adjustment to the Exercise Price that would have been effected but for the final sentence in this paragraph (d)), the number of Warrant
Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment
the aggregate Exercise Price (if applicable) payable hereunder for the increased or decreased number of Warrant Shares shall be the same
as the aggregate Exercise Price in effect immediately prior to such adjustment.

 

(e) 
Calculations. All calculations under this Section 9 shall be made to the nearest one-millionth of one cent or the nearest
share, as applicable.

 

(f)  
Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will,
at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and
prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type
of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise
to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly
deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.

 

(g) 
Notice of Corporate Events. If, while this Warrant is issued and outstanding, the Company (i) declares a dividend or any
other distribution of cash, securities or other property in respect of its Common Shares, including, without limitation, any granting
of rights or warrants to subscribe for or purchase any capital shares of the Company or any subsidiary, (ii) authorizes or approves, enters
into any agreement contemplating or solicits shareholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution,
liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute
material non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to
the applicable record or effective date on which a Person would need to hold Common Shares in order to participate in or vote with respect
to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of
the corporate action required to be described in such notice. In addition, if while this Warrant is issued and outstanding, the Company
authorizes or approves, enters into any agreement contemplating or solicits shareholder approval for any Fundamental Transaction contemplated
by Section 9(c), other than a Fundamental Transaction under clause (iii) of Section 9(c), then, except if such notice and the contents
thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental
Transaction at least ten (10) days prior to the date such Fundamental Transaction is consummated.

 

10. 
Payment of Cashless Exercise Price. Upon the cashless exercise of this Warrant pursuant to Section 4(b) or Section 9(c)
hereof, the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9)
of the Securities Act as determined as follows:

X = Y [(A-B)/A]

 

where:

 

“X” equals the number of Warrant Shares to be
issued to the Holder;

 

“Y” equals the total number of Warrant Shares
with respect to which this Warrant is then being exercised;

 

“A” equals the Closing Sale Price per Common Share
as of the Trading Day on the date immediately preceding the Exercise Date; and

 

“B” equals the Exercise Price
per Warrant Share then in effect on the Exercise Date.

 

     

     

    

 

For purposes of Rule 144 promulgated
under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a “cashless exercise”
transaction pursuant to Section 9(c) hereof shall be deemed to have been acquired by the Holder, and the holding period for the Warrant
Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take
the position that such treatment is proper at the time of such exercise).

 

For the avoidance of doubt, any exercise
of this Warrant pursuant to Section 4 hereof shall only be settled in cash.

 

 11.   Limitations on Exercise.

 

(a)  
Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder
shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving
effect or immediately prior to such exercise, would cause (i) the aggregate number of Common Shares beneficially owned by the Holder,
its Affiliates and any other Persons whose beneficial ownership of Common Shares would be aggregated with the Holder’s for purposes
of Section 13(d) of the Exchange Act (such as any other members of a Section 13(d) “group”) to exceed 9.99% (the “Maximum
Percentage”) of the total number of issued and outstanding Common Shares of the Company following such exercise, or (ii) the
combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose
beneficial ownership of Common Shares would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (such
as any other members of a Section 13(d) “group”) to exceed 9.99% of the combined voting power of all of the securities of
the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding Common Shares,
the Holder may rely on the number of outstanding Common Shares as reflected in (x) the Company’s most recent Form 10-Q or Form 10-K,
as the case may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by the Company or (z) any
other notice by the Company or its transfer agent setting forth the number of Common Shares outstanding. Upon the written request of the
Holder, the Company shall within two (2) Trading Days confirm in writing or by electronic mail to the Holder the number of Common Shares
then outstanding. In any case, the number of outstanding Common Shares shall be determined after giving effect to the conversion or exercise
of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding Common Shares
was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other
percentage specified not in excess of 9.99% as specified in such notice; provided that any such increase will not be effective until the
sixty-first (61st) day after such notice is delivered to the Company. For purposes of this Section 11(a), the aggregate number of Common
Shares or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common
Shares would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (such as any other members of a Section
13(d) “group”) shall include the Common Shares issuable upon the exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of Common Shares which would be issuable upon (x) exercise of the remaining unexercised and
non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled
portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company
which would entitle the holder thereof to acquire at any time Common Shares, including without limitation any debt, preferred share, right,
option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the
holder thereof to receive, Common Shares), is subject to a limitation on conversion or exercise analogous to the limitation contained
herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Shares
would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (such as any other members of a Section
13(d) “group”).

 

(b) 
This Section 11 shall not restrict the number of Common Shares that a Holder may receive or beneficially own in order to determine
the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated
in Section 9(c) of this Warrant.

 

12.  No
Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any
fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next
whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such
fractional shares.

 

     

     

    

 

13.  
Notices. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise
Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or
communication is delivered via confirmed e-mail prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after
the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not a Trading Day or later
than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized
overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required
to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:

 

If to the Company:

 

Attention: Amit Hasija, Chief
Financial Officer Milestone Pharmaceuticals Inc.

1111 Dr. Frederik-Philips Blvd., Suite 420 Montréal,
Québec H4M 2X6

Email: ahasija@milestonepharma.com

 

with copies (which shall not constitute notice) to:

 

Attention: Ryan Sansom Cooley LLP

500 Boylston Street, 14th Floor Boston,
Massachusetts 02116

Facsimile: (617) 937-2400 Email: rsansom@cooley.com

 

If to the Holder, to its address or e-mail address set forth
herein or on the books and records of the Company.

 

Or, in each of the above instances, to such other address
or e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days prior to the
effectiveness of such change.

 

14. 
Warrant Agent. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days’ notice to
the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged
or any corporation resulting from any consolidation or amalgamation to which the Company or any new warrant agent shall be a party or
any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services
business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly
cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s
last address as shown on the Warrant Register.

 

 15.  Miscellaneous.

 

(a) 
No Rights as a Shareholder. The Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be
entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained
in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the
rights of a shareholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization,
issue of shares, reclassification of shares, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings,
receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is
then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing
any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a shareholder of the Company,
whether such liabilities are asserted by the Company or by creditors of the Company.

 

     

     

    

 

(b)  
 Successors and Assigns. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder.
This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental
Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and
assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and
the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed
by the Company and the Holder, or their successors and assigns.

 

(c) 
Amendment and Waiver. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof
waived with the written consent of the Company and the Holder.

 

(d) 
Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein.

 

(e)  
Governing Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS
WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES
OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE
AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION
DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY
SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS
AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL
OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE
SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY
ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

 

(f) 
Headings. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed
to limit or affect any of the provisions hereof.

 

(g)  
Severability. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect,
the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby,
and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially
reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.

 

[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK]

 

     

     

    

 

IN WITNESS WHEREOF, the Company has caused this
Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

	 	MILESTONE PHARMACEUTICALS INC.
	 	 
	 	By: 	 
	 	 	Name:	Joseph G. Oliveto
	 	 	Title:	President and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]